about
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients.Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patientsUnsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myelomaSequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myelomaTuberculosis Peritonitis During Treatment of Polycythemia Vera with RuxolitinibDiffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related diseaseIs TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphomaLenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma
P50
Q38139998-074BD58D-EA89-4751-86CA-4941894FB231Q38462720-3B56FC8E-1CD3-4CBC-B9A7-18689F585F0FQ38937808-2284329C-34FB-41A5-97A0-FDADAEDA7B18Q48236958-5D0FBF3F-CD44-4EC9-BC73-2082604992AAQ50145904-31A392FA-C861-4C34-A4AA-45338A655605Q50220913-054945CD-BA5E-4D3F-8D2C-E8FD59B6286EQ50475524-5986ABA0-2E6B-455C-A20A-654577D15585Q90975093-7799444C-3CB1-45B2-8C22-FCC3D3338409Q91271501-A533F764-8CB0-49AD-B18D-099406E9FFD9Q91455672-2834AE0D-B53D-4534-938C-5FB0B0FF9AC5Q92060483-D0BFCD64-59BB-4609-A010-195409B59C51Q92178950-16495725-1CA6-484E-BFDC-3A15F47B38FFQ92924859-1D17E792-A101-4FC6-B267-C9547CFA914EQ95270431-8F6FFE8B-EEC5-49BC-AADD-FF8A1EB9704BQ96588913-81EB521D-629F-4E2A-A069-6D2584F93093
P50
description
researcher
@en
name
Junya Kuroda
@en
type
label
Junya Kuroda
@en
prefLabel
Junya Kuroda
@en
P31
P496
0000-0001-6130-1550